Radiological Technology for Targeted Radionuclide Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Radiological Technology for Targeted Radionuclide Therapy

Published:2020 Issue:12 Volume:76 Page:1237-1247
ISSN:0369-4305
Container-title:Japanese Journal of Radiological Technology
language:en
Short-container-title:Nippon Hoshasen Gijutsu Gakkai Zasshi

Author:

Hanaoka Kohei¹,Miyaji Noriaki²,Yoneyama Hiroto³,Ogawa Matsuyoshi⁴,Maeda Takamasa⁵,Sakaguchi Kenta⁶,Iimori Takashi⁷,Tsushima Hiroyuki⁸

Affiliation:

1. Institute of Advanced Clinical Medicine, Kindai University

2. Department of Nuclear Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research

3. Department of Radiological Technology, Kanazawa University Hospital

4. Radiation Department, Yokohama City University Hospital

5. Radiological Technology Section, QST Hospital, National Institutes for Quantum and Radiological Science and Technology

6. Radiology Center, Kindai University Hospital

7. Radiological Department, Chiba University Hospital

8. Department of Radiological Sciences, Ibaraki Prefectural University of Health Sciences

Publisher

Japanese Society of Radiological Technology

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/jjrt/76/12/76_2020_JSRT_76.12.1237/_pdf

Reference73 articles.

1. 2) Jimenez C, Erwin W, Chasen B. Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine-131 metaiodobenzylguanidine. Cancers (Basel) 2019; 11(7): 1018.

2. 3) Hennrich U, Kopka K. Lutathera®: the first FDA-and EMA- approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals (Basel) 2019; 12(3): 114.

3. 4) Sathekge M, Knoesen O, Meckel M, et al. 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2017; 44 (6): 1099-1100.

4. 5) Poty S, Francesconi LC, McDevitt MR, et al. α-Emitters for radiotherapy: from basic radiochemistry to clinical studies-part 2. J Nucl Med 2018; 59(7): 1020-1027.

5. 6) Morgenstern A, Apostolidis C, Kratochwil C, et al. An overview of targeted alpha therapy with 225Actinium and 213Bismuth. Curr Radiopharm 2018; 11(3): 200-208.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Practice for Nuclear Medicine Therapy; Part 1;Japanese Journal of Health Physics;2023-02-17

2. The effects of levothyroxine combined with methimazole on the clinical efficacy of hyperthyroidism treatment;PAK J PHARM SCI;2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3